StreetInsider.com News Articles

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Singah brings over 20 years of corporate and strategic finance experience across UK and US companies. She previously served as CFO at Echopoint Medical and held various roles at GSK for 11 years, including positions in mergers and acquisitions, investor relations, and finance leadership. She trained as a Chartered Accountant at EY.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Kennedy has more than 20 years of business development experience in pharmaceutical and biotechnology companies. He previously worked as Vice President of

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Singah brings over 20 years of corporate and strategic finance experience from UK and US companies. She previously served as CFO at Echopoint Medical and held various roles at GSK for 11 years, including positions in M&A and investor relations. She also worked at Amazonia Impact Ventures and Axis Spine Technologies. Singah trained as a Chartered Accountant at EY.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics names new CFO and CBO

Wed, 10 Sep 2025 03:30:12 -0400

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

Wed, 10 Sep 2025 03:30:00 -0400

Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution.
Accomplished Chief Business Officer will drive business development and partnering deals.
Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.

EDINBURGH, Scotland and LONDON, Sept. 10, 2025 /PRNewswire/ -- Resolution Therapeutics ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces the appointment of Lucy Singah as Chief Financial Officer (CFO) and Daniel

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

Wed, 10 Sep 2025 03:30:00 -0400

Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution.
Accomplished Chief Business Officer will drive business development and partnering deals.
Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

Wed, 10 Sep 2025 03:30:00 -0400

Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution.
Accomplished Chief Business Officer will drive business development and partnering deals.
Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.